@entity1262 Gene XXXX Polymorphism and Drug Resistance in Epilepsy: Evidence Based on 8604 Subjects.

@entity1 @entity1262 @entity302 @entity7658
UNASSIGNED: BACKGROUND The present study aimed to assess the role of @entity7658 polymorphism in drug-resistance in @entity302 by a meta-analysis. MATERIAL AND METHODS Databases were obtained from the Cochrane Library, MEDLINE, EMBASE, PubMed, Science Direct database, CNKI, and Wanfang up to October 2014. All the case-control association studies evaluating the role of @entity1262 @entity7658 in pharmacoresistance to anti- @entity302 drug (AED) were identified. RevMan 5.0 software was utilized to perform quantitative analyses in an allele model (C vs. T) and a genotype model (CC vs. CT+TT). RESULTS From the 189 potential studies, we included 28 articles for the meta-analysis, including 30 independent case-control studies involving 4124 drug-resistant @entity302 @entity1 and 4480 @entity302 @entity1 for whom drug treatment was effective. We excluded 164 studies because of duplication, lack of genotype data, and non-clinical research. We found that @entity7658 polymorphism was not significantly associated with drug resistance in @entity302 , either in allele model (C vs. T: OR=1.07; 95%CI: 0.95-1.19) or in genotype model (CC vs. CT+TT: OR=1.05; 95%CI: 0.89-1.24, P=0.55). Subgroup analyses suggested that in Caucasian populations there are significant differences between resistance group (NR) and control group (R) in both allele model (C vs. T: OR=1.09; 95%CI: 1.00-1.18, P=0.05) and genotype model (CC vs. CT+TT: OR=1.20; 95%CI: 1.04-1.40, P=0.01). However, we did not find this association in Asian populations. CONCLUSIONS We conclude that the @entity1262 @entity7658 polymorphism may be a genetic marker for drug resistance in @entity302 in Caucasian populations.
